News

The calculation of fVPA based on this equation resulted in a misinterpretation in 40% of measurements with around 75% of them overestimating the actual measured fVPA.

The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.

Including these agents for developmental and epileptic encephalopathies, the relatively young company has 5 programs under development to target rare neurological disorders.

A look into the numerous education series upcoming in 2021 by the Tuberous Sclerosis Alliance

New NIH-funded study tests home-based intervention in high-risk group.

Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%, according to Abbott, the test’s developer.

Further associations with lowered risk of Parkinson were observed with BMI and coffee intake.

The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.

People who were genetically predisposed to smoking behaviors were at a 63% greater risk for subarachnoid hemorrhage.

The findings showed that 64% of EEG education programs did not utilize objective measures to assess EEG milestones.

Here's what is coming soon to NeurologyLive.

Patients with an early age of onset (AO) were also more likely to receive less effective first-line oral therapy than those with later AOs.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.

The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.

Maha Radhakrishnan, MD, the Group SVP and chief medical officer at Biogen, discussed the collaborative study between Biogen and Apple that’s expected to kick off later this year.

The FDA previously declined to approve de novo classification in April 2019.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.